EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection (NCT03266653)
A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
🩺 Plain-English Summary (8th-Grade Level)
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Who can join: Review the eligibility criteria below.
Location: Children's Hosptial Los Angeles — Los Angeles, California
Age range: 1 Month to 79 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Children's Hosptial Los Angeles — Los Angeles, California
- University of California San Francisco — San Francisco, California
- Johns Hopkins — Baltimore, Maryland
- Washington University — St Louis, Missouri
- New York Medical College — Valhalla, New York
- Nationwide Children's Hosptial — Columbus, Ohio
- Children's Hospital of Pennsylvania — Philadelphia, Pennsylvania
- Medical College of Wisconsin/Children's Hospital of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (914) 594-2150
Email: mitchell_cairo@nymc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epstein-Barr Virus Infections
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas — Bethesda, Maryland
- R-MVST Cells for Treatment of Viral Infections — New York, New York
Explore by condition: All Epstein-Barr Virus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.